Matricelf https://validator.w3.org/feed/docs/rss2.html International Recognition – Matricelf Awarded a Grant from the UK-based Walkoncemore Prof. Ran Harel, M.D. Meir Clifi-Amir; Maj, Gen. (Res.) Matricelf Named Most Innovative Company of 2026 at Advanced Therapies Week in San Diego About us Investor Relations Spinal Cord Injury Matricelf signs agreement with Sheba Medical Center for clinical manufacturing and advancement of clinical program — a key milestone toward first-in-human spinal cord injury trial Hadas Shoham Nissan, Director Clinical and Regulatory affairs Home Final U.S. patent registration for the company’s 3D bioprinting technology, Omentum based scaffold and delivery system Dr. Ruchi Sharma, PhD Prof. Michael G. Fehlings, M.D., PhD Tune in to watch Matricelf’s VP R&D, Dr. Tamar Harel Adar, interviewed on Channel 10 Lori Confino Dr. Moshe Bondi, MD Patent allowance in the U.S. for the company’s 3D printing technology – omentum-based scaffold and delivery system Matricelf Announces Closing of PIPE Financing of Approximately USD 24.8 Million  Ron Mayron – Chairman of the Board Congratulations to Prof. Tal Dvir on His Election as a Fellow of the U.S. National Academy of Inventors Matricelf signs agreement with the Institute for Advanced Cellular Therapies (I-ACT) at Tel Aviv Sourasky Medical Center (Ichilov) for clinical manufacturing — a significant milestone towards the world’s first clinical trial for spinal cord injury treatment Prof. Allan D. Levi, M.D., PhD Appointment of Ron Mayron to the Company’s Board of Directors Anat Shnaiderman, QA Manager Company Profile Gil Hakim, CEO Suzana Nahum-Zilberberg Doron Birger – Chairman of the Board Matricelf’s CEO, Gil Hakim, interviewed at ‘Today’s Talk’ (Channel 13) about potential cure for paralysis Alon Sinai, PhD – Co-Founder, Deputy CEO & President Blue-and-white breakthrough: Israel to perform first-ever transplant of lab-grown spinal cord (Ynet) World’s first spinal cord transplant to take place in Israel, could allow patients to walk again Matricelf featured on Channel 12’s primetime news Matricelf to Present at Premier 2025 Spinal Cord Injury Conference Contact Us Approval by the Helsinki Committee and launch of activity in the field of 3D printing of autologous human tissues for medical applications Success in Rat Study – Final Results of Efficacy Evaluation Patent registration in the U.S. for the company’s technology – particles based on unique omentum tissue for therapeutic applications Formation of Clinical Advisory Board to accelerate First-in-Human trial strategy Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments Prof. Nicholas Theodore, M.D Final Approval by the U.S. Patent Office – Patent for 3D Bioprinting of Tissues and Organs Initiation of Comprehensive GLP Animal Safety Study for Engineered Neural Tissue to Treat Spinal Cord Injuries – A Key Milestone Toward FDA-Compliant Human Clinical Trial Successful Proof of Concept (POC) for Generating Engineered Neural Tissues from Stem Cells Using AI-Based Technology from U.S. Biotech Company Cellino Successful Safety Results – Preclinical Study in Rats Preliminary Agreements with the Ministry of Health for Use of the Company’s Product Under a Compassionate Use Program Receiving approval from the Helsinki Committee of Sheba Tel Hashomer Medical Center – First step towards compassionate treatment of spinal cord injuries Pipeline Prof. Tal Dvir, PhD – Co-Founder & CSO Tamar Harel Adar, PhD – CTO